TRICARE Prior Authorization Request Form for

semaglutide oral tablet (Rybelsus)



USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider

Drug Name:

Strength:

Dosage/Frequency (SIG):

Duration of Therapy:

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):		
1	Patient Name: Phy	Physician Name:	
	Address:	Address:	
	Sponsor ID #:	Phone #:	
		Secure Fax #:	
Step	Please complete the clinical assessment:		
2	1. Is the patient GREATER THAN or EQUAL to 18 years of	☐ Yes	□ No
	age?	Proceed to question 2	Stop
			Cov erage not approved
	2. Does the patient have a documented diagnosis of type 2 diabetes mellitus ¹ ?	☐ Yes	□ No
		Proceed to question 3	Stop
			Cov erage not approved
	3. Has the patient tried and had an inadequate response to metformin, or has a contraindication to metformin?	☐ Yes	□ No
		Proceed to question 4	Stop
		1 loceed to question 4	Cov erage not approved
	4. Is the patient able to adhere to the administration	□ Yes	□ No
	requirements (take on an empty stomach with no more than 4 oz. of water at least 30 min before the first meal		Stop
	of the day)?	Proceed to question 5	Cov erage not approved
		☐ Yes	E N
	5. Is the patient a female AND pregnant?	Stop	□ No
		Cov erage not approved	Proceed to question 6
		☐ Yes	
	6. Does the patient have a history of pancreatitis?	Stop	□ No
		Cov erage not approved	Proceed to question 7
		□ Yes	
	7. Does the patient have a personal or family history of medullary thyroid carcinoma (MTC)?	Stop	□ No
		Cov erage not approved	Proceed to question 8
	Does the patient have multiple endocrine neoplasia syndrome type 2 (MEN2)?	□ Yes	
		Stop	□ No Proceed to question 9
		Cov erage not approved	i loceed to question 3

TRICARE Prior Authorization Request Form for semaglutide oral tablet (Rybelsus)

9. Patient and provider acknowledge that Rybelsus has not been shown to reduce the risk of major adverse □ No cardiovas cular events (cardiovas cular death, non-fatal ☐ Yes Stop myocardial infarction, or non-fatal stroke) in adults with Sign and date below type 2 diabetes mellitus and established cardiovas cular Coverage not approved disease? ¹ Non-FDA approved uses are not approved including weight loss (obesity) or type 1 diabetes mellitus Step I certify the above is true to the best of my knowledge. Please sign and date: 3 Prescriber Signature Date [25 Aug 2023] For Internal Use Only Duration of Approval: Approved: month(s) ☐ Denied: Authorized By: PA#: ☐ Incomplete/Other:

Date Decision Rendered:

Date Faxed to MD: